Immunome Inc.
IMNMNasdaq
$22.32
↑ +0.5%Jul 17 close · end-of-day
Price
1Y↑ +130.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.5B
Enterprise Value
$1.9B
P/E
—
P/S
628.9
P/B
4.3
EV/EBITDA
—
PEG
—
FCF Yield
-8.1%
Dividend Yield
—
Revenue (TTM)
$4.0M
Net Income (TTM)
-$224.6M
Free Cash Flow (TTM)
-$205.5M
Gross Margin
—
Operating Margin
-5947.9%
Net Margin
-5593.8%
ROE
-38.1%
ROIC
-3148.0%
Debt / Equity
—
Net Cash
$582.7M
Return 1Y
+113.6%
Company profile
Immunome, Inc. discovers and develops antibody therapeutics for oncology and infectious disease. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
- CEO
- Purnanand D. Sarma
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Headquarters
- Washington
- Website
- immunome.com
Management & directors
- Horn KinneyCHIEF BUSINESS OFFICER
- Lechleider RobertChief Medical Officer
- Rosett MaxChief Financial Officer
- Higgins JackChief Scientific Officer
- Siegall Clay BPresident and CEO
- Tsai PhilipChief Technical Officer
Roles derived from SEC Form 4 filings.
Earnings
IMNM Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$0.00↓ -100.0%
Diluted EPS-$0.48↓ -7.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $14.0M | $9.0M | $6.9M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$12.3M | -$25.2M | -$36.9M | -$109.5M | -$305.8M | -$224.1M |
| Net income | -$17.8M | -$24.7M | -$36.9M | -$106.8M | -$293.0M | -$212.4M |
| Diluted EPS | -$5.26 | -$2.14 | -$3.09 | -$5.38 | -$5.00 | -$2.43 |
| Operating cash flow | -$12.1M | -$18.2M | -$28.7M | -$7.6M | -$110.8M | -$190.9M |
| Free cash flow | -$12.7M | -$18.3M | -$28.9M | -$8.4M | -$118.0M | -$200.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | -781.4% | -3382.4% | -3228.8% |
| Net margin | — | — | — | -761.9% | -3240.4% | -3060.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $2.9M | $2.7M | $2.9M | $4.0M | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$40.0M | -$50.5M | -$83.0M | -$44.6M | -$46.5M | -$60.1M | -$72.9M | -$59.3M |
| Net income | -$36.1M | -$47.1M | -$80.2M | -$41.6M | -$43.4M | -$57.5M | -$69.9M | -$53.8M |
| Diluted EPS | -$0.60 | -$0.78 | -$1.11 | -$0.52 | -$0.50 | -$0.65 | -$0.76 | -$0.48 |
| Operating cash flow | -$23.4M | -$34.2M | -$42.1M | -$53.1M | -$49.4M | -$40.5M | -$48.0M | -$58.6M |
| Free cash flow | -$25.7M | -$35.7M | -$43.2M | -$56.7M | -$50.3M | -$41.6M | -$52.0M | -$61.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1692.4% | -1736.2% | -3030.3% | -1525.5% | -1157.6% | — | — | — |
| Net margin | -1528.0% | -1618.6% | -2930.9% | -1423.1% | -1080.9% | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-07 | Barchas Isaac | Sale | 16,906 | $24.20 | $409,125.20 | filing |
| 2026-07-07 | Horn Kinney· CHIEF BUSINESS OFFICER | Sale | 1,092 | $25.00 | $27,300.00 | filing |
| 2026-07-07 | Horn Kinney· CHIEF BUSINESS OFFICER | Option exercise | 1,092 | $12.92 | $14,108.64 | filing |
| 2026-07-06 | Barchas Isaac | Sale | 83,094 | $24.11 | $2.0M | filing |
| 2026-07-02 | Barchas Isaac | Sale | 75,665 | $22.35 | $1.7M | filing |
| 2026-07-02 | Barchas Isaac | Sale | 24,335 | $23.33 | $567,735.55 | filing |
| 2026-07-02 | Lechleider Robert· Chief Medical Officer | Sale | 22,714 | $21.95 | $498,572.30 | filing |
| 2026-07-02 | Lechleider Robert· Chief Medical Officer | Option exercise | 55,000 | $8.73 | $480,150.00 | filing |
| 2026-07-02 | Lechleider Robert· Chief Medical Officer | Sale | 16,072 | $23.44 | $376,727.68 | filing |
| 2026-07-02 | Lechleider Robert· Chief Medical Officer | Sale | 16,214 | $22.76 | $369,030.64 | filing |
| 2026-06-30 | Barchas Isaac | Sale | 101,050 | $21.12 | $2.1M | filing |
| 2026-06-25 | Lechleider Robert· Chief Medical Officer | Sale | 40,580 | $19.56 | $793,744.80 | filing |
| 2026-06-25 | Lechleider Robert· Chief Medical Officer | Option exercise | 55,000 | $8.73 | $480,150.00 | filing |
| 2026-06-25 | Lechleider Robert· Chief Medical Officer | Sale | 14,420 | $20.66 | $297,917.20 | filing |
| 2026-06-15 | Rosett Max· Chief Financial Officer | Sale | 60,000 | $18.23 | $1.1M | filing |
| 2026-06-15 | Rosett Max· Chief Financial Officer | Option exercise | 60,000 | $1.05 | $63,000.00 | filing |
| 2026-06-05 | BIENAIME JEAN JACQUES | Sale | 10,000 | $19.41 | $194,100.00 | filing |
| 2026-06-05 | BIENAIME JEAN JACQUES | Buy | 6,000 | $19.48 | $116,880.00 | filing |
| 2026-06-05 | BIENAIME JEAN JACQUES | Buy | 3,500 | $19.46 | $68,110.00 | filing |
| 2026-06-05 | BIENAIME JEAN JACQUES | Buy | 1,000 | $19.27 | $19,270.00 | filing |
| 2026-06-05 | BIENAIME JEAN JACQUES | Sale | 500 | $19.44 | $9,720.00 | filing |
| 2026-05-15 | BIENAIME JEAN JACQUES | Buy | 5,000 | $20.70 | $103,500.00 | filing |
| 2026-04-02 | Rosett Max· Chief Financial Officer | Sale | 63,656 | $21.91 | $1.4M | filing |
| 2026-04-02 | Higgins Jack· Chief Scientific Officer | Sale | 9,438 | $21.64 | $204,238.32 | filing |
| 2026-04-02 | Rosett Max· Chief Financial Officer | Option exercise | 39,713 | $1.35 | $53,612.55 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.